Supernus Pharmaceuticals (SUPN) EPS (Basic) Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) EPS (Basic) Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -301.82% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.21% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.09% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 13.91% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 31.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 388.06% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -350.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -350.30% |
| Dec 31, 2025 | -126.14% |
| Sep 30, 2025 | -214.15% |
| Jun 30, 2025 | 10.94% |
| Mar 31, 2025 | -8,213.26% |
| Dec 31, 2024 | 1,191.16% |
| Sep 30, 2024 | 338.89% |
| Jun 30, 2024 | 2,485.70% |
| Mar 31, 2024 | -99.16% |
| Dec 31, 2023 | -95.47% |
| Sep 30, 2023 | -999.73% |
| Jun 30, 2023 | -110.31% |
| Mar 31, 2023 | -35.13% |
| Dec 31, 2022 | 933.54% |
| Sep 30, 2022 | -91.98% |
| Jun 30, 2022 | -67.11% |
| Mar 31, 2022 | 346.60% |
| Dec 31, 2021 | -92.14% |
| Sep 30, 2021 | -46.63% |
| Mar 31, 2021 | -73.73% |